Cingulate Inc (CING)

$4.16 +0.12 (2.97%)
Market Cap 21.27M
Revenue (ttm) 0.00
Net Income (ttm) -15.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 64,700
Avg Vol 133,068
Day's Range N/A - N/A
Shares Out 5.27M
Stochastic %K 37%
Beta -0.74
Analysts Strong Sell
Price Target $29.00

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmac...

Industry: Biotechnology
Sector: Healthcare
Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
Sanaci
Sanaci Aug. 18 at 6:50 PM
$TNXP $CING That was so Easy!
0 · Reply
ZacksResearch
ZacksResearch Aug. 18 at 5:43 PM
$CING CEO Shakeup — what does it mean for investors? ⚡️ Shane Schaffer has been placed on administrative leave over legal matters, with CFO Jennifer Callahan stepping in as interim CEO and Jay Roberts named Executive Chairman. The Board reaffirmed focus on advancing CTx-1301 after filing its NDA with the FDA in July. What today’s leadership shift means for $CING investors 👉 https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-8233&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_8233
0 · Reply
activehybrid
activehybrid Aug. 18 at 1:25 PM
$CING any news on cingulate ?
2 · Reply
JuanDonde10
JuanDonde10 Aug. 15 at 10:30 PM
$CING Wow what a ride with this one and a violent CEO. What’s the best time to buy this based off the drug approval and commercialization timeline? I’d hate to buy and watch it fluctuate from 3-5 for months. Sorry, I know Pharma stocks are hit or miss but this looks like it has potential.
1 · Reply
Duke1979
Duke1979 Aug. 15 at 7:19 PM
$TNXP I’m in now but will be selling with staggered sell orders on the way up. Taking my profits to $CING for the big 💥
2 · Reply
Bogdanoff2142
Bogdanoff2142 Aug. 15 at 7:03 PM
$CING fk it im all in
0 · Reply
VicTruth17
VicTruth17 Aug. 15 at 4:38 PM
$CING say no to choking Shane!
1 · Reply
DaStockman
DaStockman Aug. 15 at 1:19 PM
$CING Good update and for now a wise decision. https://www.cingulate.com/news-releases/news-release-details/cingulate-provides-management-team-update
3 · Reply
Mazinga_Mong
Mazinga_Mong Aug. 14 at 4:50 PM
$CING
0 · Reply
MRTunity
MRTunity Aug. 14 at 4:43 PM
$CING tried to buy 1K at $3.60 yesterday and missed by 2cents, should have just slapped the ask … UGH at least my position here at $4.23 back in profit
4 · Reply
Latest News on CING
Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 4 days ago

Cingulate Provides Management Team Update

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 13 days ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 2 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 3 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 4 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 5 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 8 months ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 10 months ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 11 months ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 1 year ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 1 year ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 1 year ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 1 year ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 1 year ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 12, 2023, 3:45 PM EDT - 2 years ago

Cingulate, Indegene to Participate in Benzinga All Live Access Event

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

May 10, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

May 3, 2023, 6:45 AM EDT - 2 years ago

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Apr 4, 2023, 6:45 AM EDT - 2 years ago

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Mar 13, 2023, 6:45 AM EDT - 2 years ago

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Sanaci
Sanaci Aug. 18 at 6:50 PM
$TNXP $CING That was so Easy!
0 · Reply
ZacksResearch
ZacksResearch Aug. 18 at 5:43 PM
$CING CEO Shakeup — what does it mean for investors? ⚡️ Shane Schaffer has been placed on administrative leave over legal matters, with CFO Jennifer Callahan stepping in as interim CEO and Jay Roberts named Executive Chairman. The Board reaffirmed focus on advancing CTx-1301 after filing its NDA with the FDA in July. What today’s leadership shift means for $CING investors 👉 https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-8233&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_8233
0 · Reply
activehybrid
activehybrid Aug. 18 at 1:25 PM
$CING any news on cingulate ?
2 · Reply
JuanDonde10
JuanDonde10 Aug. 15 at 10:30 PM
$CING Wow what a ride with this one and a violent CEO. What’s the best time to buy this based off the drug approval and commercialization timeline? I’d hate to buy and watch it fluctuate from 3-5 for months. Sorry, I know Pharma stocks are hit or miss but this looks like it has potential.
1 · Reply
Duke1979
Duke1979 Aug. 15 at 7:19 PM
$TNXP I’m in now but will be selling with staggered sell orders on the way up. Taking my profits to $CING for the big 💥
2 · Reply
Bogdanoff2142
Bogdanoff2142 Aug. 15 at 7:03 PM
$CING fk it im all in
0 · Reply
VicTruth17
VicTruth17 Aug. 15 at 4:38 PM
$CING say no to choking Shane!
1 · Reply
DaStockman
DaStockman Aug. 15 at 1:19 PM
$CING Good update and for now a wise decision. https://www.cingulate.com/news-releases/news-release-details/cingulate-provides-management-team-update
3 · Reply
Mazinga_Mong
Mazinga_Mong Aug. 14 at 4:50 PM
$CING
0 · Reply
MRTunity
MRTunity Aug. 14 at 4:43 PM
$CING tried to buy 1K at $3.60 yesterday and missed by 2cents, should have just slapped the ask … UGH at least my position here at $4.23 back in profit
4 · Reply
fullobullz
fullobullz Aug. 14 at 3:36 PM
$CING I bet Lincoln was hoping Cing would hit the atm yesterday on the dip.
0 · Reply
Arcides
Arcides Aug. 14 at 2:28 PM
$CING potential shakeout
0 · Reply
sam9420
sam9420 Aug. 14 at 2:27 PM
$CING there are an order with 50k shares at 3.95 $
1 · Reply
DaStockman
DaStockman Aug. 14 at 7:34 AM
$CING Know what you own. This has massive potential from here. https://www.bbc.co.uk/news/articles/crr2j792drro
0 · Reply
sam9420
sam9420 Aug. 14 at 7:21 AM
$CING shane not Elon musk for Tesla . Cing will continue with or without shanne 💪. #Be confident with what you have 👌. I have now 20k shares of cing at average 4.10$ with 4k shares yesterday at 3.54$. My sell order more than 25$.
0 · Reply
chinchinbull
chinchinbull Aug. 14 at 5:18 AM
$CING It appears that significant manipulation is expected prior to the FDA decision. Market makers will likely suppress the price to accumulate positions, and retail investors may face challenges in countering this tactic. This has reminded me of an old story: Would purchasing some deep put options be a viable strategy?
1 · Reply
catalysthunter
catalysthunter Aug. 14 at 2:45 AM
$CING this is too much. They are not defending the price at all. There would be no news until PDUFA confirmation which would require 2month+ from now. US patent confirmation (which we don’t even know whether it gonna be accepted or rejected) needs time until end of 2025 to 2026. Which still needs plenty of time. CEO is in big trouble, and COO is out during very important period for the company. Trump wants pills to be priced downward AND there would be no news coming at least for 2~3 months. Which means the price can go fall to near 2$. I know we need to be patient at least a year, but still worried about the price we are at. If the whole market turns into bear market? then $1~2 is not a impossible scenario.
2 · Reply
EFhutton420
EFhutton420 Aug. 13 at 9:21 PM
$CING https://www.youtube.com/watch?v=HbAH1ZMjLls
0 · Reply
activehybrid
activehybrid Aug. 13 at 9:07 PM
$CING was Peter Werth informed and knew that was coming ? Most likely
0 · Reply
EFhutton420
EFhutton420 Aug. 13 at 9:04 PM
$CING aren't they due to release earnings this week?
1 · Reply
lennymazur
lennymazur Aug. 13 at 9:02 PM
$CING Schaffer is notoriously MAGA, he will get quick approval by Don's FDA ;)
1 · Reply
denhopeforbest
denhopeforbest Aug. 13 at 8:49 PM
$CING burn the ceo at the stake. innocent until proven guilty? maybe just a scandal.
0 · Reply